Forecast Earnings Dividend Ownership $12.64-0.35 (-2.69 %) Updated Mar 12, 2021. This price target is based on 10 analysts offering 12 month price targets for BioCryst Pharmaceuticals in the last 3 months. One share of BCRX stock can currently be purchased for approximately $13.24. The stock lies in the middle of a wide and strong rising trend in the short … BioCryst Pharmaceuticals Stock Forecast NASDAQ:BCRX. 8 of the analysts rate the stock as a “Buy”. Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; Consensus Rating: Buy; Consensus Price Target: $9.07; Forecasted Upside: 48.71 %; Number of Analysts: 10; Breakdown: 0 Sell Ratings; 3 Hold Ratings; 7 Buy Ratings; 0 Strong Buy Ratings $ 6.10 As of 12/4/2020 01:00 AM ET +0.96 (18.68%) … The biotechnology company earns $-108,900,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. Related Link: Are Americans Ready To Travel? Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. View insider buying and selling activity for BioCryst Pharmaceuticals or or view top insider-buying stocks. Never miss a profitable trade. The lowest EPS estimate is ($0.31) and the highest is ($0.23). The 12-month stock price forecast is 13.78, which is an increase of 5.92% from the latest price. 12, 2021) (BioCryst Pharmaceuticals, Inc.) BCRX latest price $12.6150 (-2.4%) ($12.6150 - $12.6150) on Fri. Mar. BioCryst Pharmaceuticals' management team includes the following people: President, Chief Executive Officer & Director, Chief Financial Officer & Senior Vice President, Chief Medical Officer & Senior Vice President, Secretary, Chief Legal Officer & Senior VP, Chief Business Officer & Senior Vice President, Start Your Risk-Free Trial Subscription Here, 3 Homebuilder Stocks Making Constructive Moves, Whatever You Believe About Sundial Growers, You Could Be Right, SunPower Stock is a Best of Breed Solar Play, The Exodus Movement, Inc Ushers In A New Age Of IPO, Ford Stock Gains Big on Upgrade at Barclays, Nike Slips On Earnings, Traction Forecast For Later In The Year, FedEx Breaks Out On Q3 Earnings And Outlook, Cintas Falls On Great Results, Growth Is Back On The Table, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, First Week of May 21st Options Trading For BioCryst Pharmaceuticals (BCRX), BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer, BioCryst to Host Virtual R&D Day on March 22, 2021, Biocryst’s berotralstat granted early access for HAE in France, Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France, BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema, Why BioCryst Pharmaceuticals Stock Is Popping Today, BioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema, BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema, BioCryst Pharmaceuticals (BCRX) Q4 2020 Earnings Call Transcript, Why BioCryst Pharmaceuticals Stock Is Falling Today, BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates, BioCryst Pharmaceuticals, Inc. to Host Earnings Call, BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones. Detailed Estimate. The average price target is $9.07, with a high forecast of $13.00 and a low forecast of $4.50. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. © 2020 Cable News Network. View institutional ownership trends for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Long since 1.90's. BCRX stock forecasts by analyst. Biocryst Pharmaceuticals Stock Forecast, BCRX stock price prediction. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. BCRX forecasts Videos only. Their forecasts range from $6.00 to $16.00. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. The consensus price target of analysts on Wall Street is $13.9, which implies an increase of 3.42% to the stock’s current value. Facebook. BCRX Stock Predictions. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. View BioCryst Pharmaceuticals, Inc. BCRX investment & stock information. BioCryst Pharmaceuticals has received 51.72% “outperform” votes from our community. Only 4.30% of the stock of BioCryst Pharmaceuticals is held by insiders. Twitter. Biocryst Pharmaceuticals Inc. Stock Price Forecast, "BCRX" Predictons for2021 Should I buy or sell BCRX? © American Consumer News, LLC dba MarketBeat® 2010-2021. View today's stock price, news and analysis for BioCryst Pharmaceuticals Inc. (BCRX). BCRX stock forecast for the next 10 days by pretiming. BCRX stock forecast Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.. BioCryst Pharmaceuticals made public its earnings report on February 25 ; BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. BCRX Related ETF s. Symbol %Holdings 3M %Chg; BCRX +55.67% : Biocryst Pharma Inc: XBI : 1.36% +2.98% : S&P Biotech SPDR: IWM : 0.08% +22.75% : Russell 2000 Ishares ETF: IBB : 0.19% +3.04% : Nasdaq Biotechnology Ishares ETF: IWO : 0.13% +15.30% : Russell 2000 Growth Ishares ETF: VTI : 0% +9.05% : Total Stock Market ETF Vanguard: Symbol %Holdings 3M %Chg; BCRX … BCRX Stock Analysis - [Full Report] Free Signup: Advanced stock screener. BioCryst climbs after FDA approval for Rapivab in infants, BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older, BioCryst Pharmaceuticals Reaches Analyst Target Price, The GameStop frenzy convinced more people to search 'how to buy stocks' than last year's surge, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Notifications > RSS.feed pretiming (Go to RSS.feed) > Pretiming analysis will be updated one by one at GMT 0:00 everyday > Please read a guide how to use pretiming analysis. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. View today's stock price, news and analysis for BioCryst Pharmaceuticals Inc. (BCRX). 0. The extremes of the forecast give a target low and a target high price of $9 and $16 respectively. Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. PEG N/A. Disclaimer. Winifred Gerald - March 18, 2021. Learn more. ... BCRX Stock Predictions, Articles, and Biocryst Pharma Inc News. BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021. Learn about financial terms, types of investments, trading strategies and more. Jon P. Stonehouse has an approval rating of 40% among BioCryst Pharmaceuticals' employees. View insider buying and selling activity for BioCryst Pharmaceuticals or view top insider-selling stocks. BCRX, 1D. NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price Target and Predictions. BioCryst Pharmaceuticals is headquartered at 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. Chart is setting up perfectly for 3/22 Data readout. Stock price today. The trading price of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) floating lower at last check on Monday, Jan 11, closing at $7.74, -3.26% lower than its previous close. The company was founded in 1986 and is headquartered in Durham, NC. The 12-month stock price forecast is 13.78, which is an increase of 5.92% from the latest price. The extremes of the forecast give a target low and a target high price of $9 and $16 respectively. View analyst ratings for BioCryst Pharmaceuticals or view top-rated stocks. All times are ET. Should I buy or sell BCRX stock? Limited Time Only. Facebook. This suggests that the stock has a possible downside of 11.0%. Long. Price Target Factset: FactSet Research Systems Inc.2019. You may vote once every thirty days. Analyzing BioCryst Pharmaceuticals (NASDAQ:BCRX) stock? BioCryst Pharmaceuticals closed on Monday at $11.10 after barely changing a -0.45%. Earnings for BioCryst Pharmaceuticals are expected to decrease in the coming year, from ($0.96) to ($0.97) per share. They use their proprietary Smart Scan and Trade Triangle technology to analyze the stock and you will get an instant report on how BCRX will perform in the near future. Apr. BCRX Price $12.64. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. 3M 12M Bollinger Which way will BCRX go? Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, Steve Aselage and Thomas R Staab II. View our earnings forecast for BioCryst Pharmaceuticals. (Add your “outperform” vote. According to analysts' consensus price target of $11.78, BioCryst Pharmaceuticals has a forecasted downside of 11.0% from its current price of $13.24. Increased. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Find out now with a free analysis on BioCryst Pharmaceuticals. BCRX: BioCryst Pharmaceuticals, Inc. According to 10 analysts, the average rating for BCRX stock is "Buy." Price target in 14 days: 14.810 USD. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All Strong Buy Buy Hold Sell Strong Sell. The BioCryst stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, ... BCRX Analyst Forecast > Blogger Opinions. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare Top Brokerages Here. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Find the latest BioCryst Pharmaceuticals, Inc. (BCRX) stock quote, history, news and other vital information to help you with your stock trading and investing. BCRX Only Stock to Own. Report Split - Wrong Prices/Values Doesn't exist anymore Wrong Signals NASDAQ Stock Exchange > Biotechnology > Healthcare × Create a Watchlist. The official website for BioCryst Pharmaceuticals is www.biocryst.com. Dividend … If I had to chose one stock to own this next year you are looking at it. In this case, analysts estimate an annual EPS growth of -0.04% for the year and -0.3% for the next year. A Warner Media Company. Earnings vs Market: BCRX is forecast to remain unprofitable over the next 3 years. Evercore ISI Group. View which stocks are hot on social media with MarketBeat's trending stocks report. Identify stocks that meet your criteria using seven unique stock screeners. 1, 2003 - Fri. Mar. Get daily stock ideas top-performing Wall Street analysts. BCRX Stock Analysis Overview What this means: Biocryst Pharma Inc (BCRX) gets an Overall Rank of 56, which is an above average rank under InvestorsObserver's stock ranking system. High Growth Earnings: BCRX is forecast to remain unprofitable over the next 3 years. BioCryst Pharmaceuticals does not currently pay a dividend. sentiment. Learn everything you need to know about successful options trading with this three-part video course. WhatsApp. BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX.". Find market predictions, BCRX financials and market news. Pinterest . 52 Week High $13.92. The average price target represents a 3.00% upside from the last price of $9.57. BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. This price target is based on 10 analysts offering 12 month price targets for BioCryst Pharmaceuticals in the last 3 months. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. BioCryst Pharmaceuticals has received a consensus rating of Buy. shlobby. 70. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its earnings results on Wednesday, February, 24th. Vote “Outperform” if you believe BCRX will outperform the S&P 500 over the long term. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Trading Information. View all of BCRX's competitors. BCRX stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, UBS Asset Management Americas Inc., Credit Suisse AG, Victory Capital Management Inc., Barclays PLC, Pura Vida Investments LLC, SG Americas Securities LLC, and Edge Wealth Management LLC. 10 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains.
, , Dj ötzi Wikipedia, Deggendorfer Zeitung Polizeibericht, Grill Und Pizza Haus Hammelburg, Bowling Moers Preise, Griechische Antike Malerei,
Neue Kommentare